ZNTL
Zentalis Pharmaceuticals, Inc.
Key Financials
Operating Income
$-152808000
↑ 20.1%
Revenue
$0
↓ 100.0%
Net Income
$-137060000
↑ 17.4%
EPS (Diluted)
$-1.91
↑ 18.0%
Total Assets
$289.0M
↓ 32.9%
Total Liabilities
$72.8M
↓ 21.9%
Shareholders' Equity
$216.2M
↓ 35.9%
Cash & Equivalents
$36.0M
↑ 6.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/27/2026 | View on SEC |
| 3 | 5/27/2026 | View on SEC |
| DEFA14A | 5/27/2026 | View on SEC |
| 8-K | 5/27/2026 | View on SEC |
| 8-K | 5/21/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| DEFA14A | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ZNTL |
| Company Name | Zentalis Pharmaceuticals, Inc. |
| CIK | 1725160 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (858) 263-4333 |